The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy

Journal of the American Society of Hypertension

Volumn 10, Issue 4, 2016, Pages 352-359

  Mathew, Roy O ^a,c,d   Nayer, Ali ^b   Asif, Arif ^c  

^a STRATTON VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Jersey Shore University   (United States)

^d WJB Dorn VA Medical Center   (United States)

Author keywords

endothelial dysfunction; hemolytic uremic syndrome; Malignant hypertension; thrombotic microangiopathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; COMPLEMENT COMPONENT C5 INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; RENIN ANGIOTENSIN SYSTEM INHIBITOR; RENIN INHIBITOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; XANTHINE OXIDASE INHIBITOR; ADAMTS13 PROTEIN, HUMAN;

ENDOTHELIUM; ENDOTHELIUM INJURY; HISTOPATHOLOGY; HUMAN; ISCHEMIA; MALIGNANT HYPERTENSION; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; COMPLEMENT ALTERNATIVE PATHWAY; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADAMTS13 PROTEIN; COMPLEMENT PATHWAY, ALTERNATIVE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, MALIGNANT; THROMBOTIC MICROANGIOPATHIES;

EID: 84952931675     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2015.12.007     Document Type: Review

References (35)

1. T.F. Luscher The endothelium target and promoter of hypertension? Hypertension 15 1990 482 485
2. M. Bielaszewska, C. Ruter, L. Kunsmann, L. Greune, A. Bauwens, W. Zhang, and et al. Enterohemorrhagic Escherichia coli hemolysin employs outer membrane vesicles to target mitochondria and cause endothelial and epithelial apoptosis PLoS Pathog 9 2013 e1003797
3. R. Cofiell, A. Kukreja, K. Bedard, Y. Yan, A.P. Mickle, M. Ogawa, and et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS Blood 125 2015 3253 3262
4. S. Jodele, B.L. Laskin, C.E. Dandoy, K.C. Myers, J. El-Bietar, S.M. Davies, and et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury Blood Rev 29 2015 191 204
5. T. Barbour, S. Johnson, S. Cohney, and P. Hughes Thrombotic microangiopathy and associated renal disorders Nephrol Dial Transplant 27 2012 2673 2685
6. J.N. George, and C.M. Nester Syndromes of thrombotic microangiopathy N Engl J Med 371 2014 1847 1848
7. B.R. Silva, L. Pernomian, and L.M. Bendhack Contribution of oxidative stress to endothelial dysfunction in hypertension Front Physiol 3 2012 441
8. R.A. Preston, W. Jy, J.J. Jimenez, L.M. Mauro, L.L. Horstman, M. Valle, and et al. Effects of severe hypertension on endothelial and platelet microparticles Hypertension 41 2003 211 217
9. H. Izzedine Anti-VEGF cancer therapy in nephrology practice Int J Nephrol 2014 2014 143426
10. M. Noris, and G. Remuzzi Medical progress: atypical hemolytic-uremic syndrome N Engl J Med 361 2009 1676 1687
11. L.B. Zimmerhackl, N. Besbas, T. Jungraithmayr, N. van de Kar, H. Karch, D. Karpman, and et al. European Study Group for Haemolytic Uraemic S, Related D: Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome Semin Thromb Hemost 32 2006 113 120
12. C.M. Taylor Hemolytic-uremic syndrome and complement factor H deficiency: clinical aspects Semin Thromb Hemost 27 2001 185 190
13. A.S. De Vriese, S. Sethi, J. Van Praet, K.A. Nath, and F.C. Fervenza Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: an Etiologic Approach J Am Soc Nephrol 26 2015 2917 2929
14. J.J. Jimenez, W. Jy, L.M. Mauro, L.L. Horstman, C. Soderland, and Y.S. Ahn Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation Br J Haematol 123 2003 896 902
15. G.N. Chironi, C.M. Boulanger, A. Simon, F. Dignat-George, J.M. Freyssinet, and A. Tedgui Endothelial microparticles in diseases Cell Tissue Res 335 2009 143 151
16. A. Nayer, and A. Asif Atypical hemolytic-uremic syndrome: a clinical review Am J Ther 2014 [Epub ahead of print], http://dx.doi.org/10.1097/MJT.0b013e31829b59dc
17. L.A. Lotta, M. Mariani, D. Consonni, I. Mancini, R. Palla, A. Maino, and et al. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura Br J Haematol 151 2010 488 494
18. J.A.K. Hovinga, S.K. Vesely, D.R. Terrell, B. Lämmle, and J.N. George Survival and relapse in patients with thrombotic thrombocytopenic purpura Blood 115 2010 1500 1511
19. L.B. Zimmerhackl E. coli, antibiotics, and the hemolytic-uremic syndrome N Engl J Med 342 2000 1990 1991
20. L. Te Riet, J.H. van Esch, A.J. Roks, A.H. van den Meiracker, and A.H. Danser Hypertension: renin-angiotensin-aldosterone system alterations Circ Res 116 2015 960 975
21. B. Grunfeld, M. Gimenez, S. Liapchuc, J. Mendilaharzu, and C. Gianantonio Systemic hypertension and plasma renin activity in children with the hemolytic-uremic syndrome Int J Pediatr Nephrol 3 1982 211 214
22. W. Proesmans, A. VanCauter, L. Thijs, and P. Lijnen Plasma renin activity in haemolytic uraemic syndrome Pediatr Nephrol 8 1994 444 446
23. Y. Shibagaki, and T. Fujita Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other? Hypertens Res 28 2005 89 95
24. C. Nzerue, K. Oluwole, D. Adejorin, P. Paueksakon, R. Fremont, R. Akatue, and et al. Malignant hypertension with thrombotic microangiopathy and persistent acute kidney injury (AKI) Clin Kidney J 7 2014 586 589
25. B.J. van den Born, N.V. van der Hoeven, E. Groot, P.J. Lenting, J.C. Meijers, M. Levi, and et al. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension Hypertension 51 2008 862 866
26. E.C. Lian Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond Semin Thromb Hemost 31 2005 625 632
27. C. Pecoraro, A.V. Ferretti, E. Rurali, M. Galbusera, M. Noris, and G. Remuzzi Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab Am J kidney Dis 66 2015 1067 1070
28. S. Chaturvedi, D. Carcioppolo, L. Zhang, and K.R. McCrae Management and outcomes for patients with TTP: analysis of 100 cases at a single institution Am J Hematol 88 2013 560 565
29. Y. Zheng, H. Hong, H.M. Reeves, and R.W. Maitta Absolute immature platelet count helps differentiate thrombotic thrombocytopenic purpura from hypertension-induced thrombotic microangiopathy Transfus Apher Sci 51 2014 54 57
30. L. Mouthon, A. Berezne, G. Bussone, L.H. Noel, P.M. Villiger, and L. Guillevin Scleroderma renal crisis: a rare but severe complication of systemic sclerosis Clin Rev Allergy Immunol 40 2011 84 91
31. C. Manrique, G. Lastra, M. Gardner, and J.R. Sowers The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress Med Clin North Am 93 2009 569 582
32. M. Satoh, Y. Takahashi, T. Tabuchi, Y. Minami, M. Tamada, K. Takahashi, and et al. Cellular and molecular mechanisms of statins: an update on pleiotropic effects Clin Sci (Lond) 129 2015 93 105
33. P. Higgins, J. Dawson, K.R. Lees, K. McArthur, T.J. Quinn, and M.R. Walters Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis Cardiovasc Ther 30 2012 217 226
34. T. Nagasawa, M.A. Hye Khan, and J.D. Imig Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib Clin Exp Pharmacol Physiol 39 2012 454 461
35. E. Nestoridi, R.I. Kushak, O. Tsukurov, E.F. Grabowski, and J.R. Ingelfinger Role of the renin angiotensin system in TNF-alpha and Shiga-toxin-induced tissue factor expression Pediatr Nephrol 23 2008 221 231